L-carnitine for treatment of pegasparaginase-induced hepatotoxicity Journal Article


Authors: Alshiekh-Nasany, R.; Douer, D.
Article Title: L-carnitine for treatment of pegasparaginase-induced hepatotoxicity
Abstract: Introduction: Similar to pediatric regimens, multiple doses of L-asparaginase (PEG-Asp) are being increasingly used in adults with newly diagnosed acute lymphoblastic leukemia (ALL) with promising results. One of the most common side effects of the drug in adults is high-grade hyperbilirubinemia and transaminitis. Despite being almost always reversible and may not recur, clinicians may still be reluctant to continue with PEG-Asp in patients with liver toxicity, losing the benefit from multiple doses of the drug. Case Report: We describe a case of adult ALL who developed PEG-Asp-related high grade liver toxicity. The rising hyperbilirubinemia and transaminitis rapidly and permanently reversed using the amino-acid derivative L-carnitine. This case goes in line with similar observations in animal models and humans. Conclusion: L-Carnitine may show therapeutic benefit in PEG-Asp-related hepatotoxicity and should be considered in clinical trials of the drug. (C) 2016 S. Karger AG, Basel
Keywords: hepatitis; acute lymphoblastic leukemia; liver; asparaginase; toxicity; l-carnitine; choleostatic
Journal Title: Acta Haematologica
Volume: 135
Issue: 4
ISSN: 0001-5792
Publisher: S. Karger AG  
Date Published: 2016-05-01
Start Page: 208
End Page: 210
Language: English
ACCESSION: WOS:000375775000003
DOI: 10.1159/000442342
PROVIDER: wos
PUBMED: 26841296
Notes: Article -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Dan Douer
    87 Douer